InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.14
(
0.01%
)
Bitcoin
64,243.36
(
0.38%
)
Post# of 4273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Methinks

Send PM Follow Ignore
Followers 4
Posts 2153
Boards Moderated 0
Alias Born 09/06/2003

Methinks

Re: None

Wednesday, 05/23/2018 4:49:36 AM

Wednesday, May 23, 2018 4:49:36 AM

Post# of 4273
Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness

Synergy Pharmaceuticals Scored $1.4B Valuation For Its Proposed Solution To Ironwood's Diarrhea

https://finance.yahoo.com/news/biotech-ceo-presents-merck-500m-115300125.html

Synergy Pharmaceuticals (SGYP) touted Trulance as an alternative to Ironwood's Linzess for chronic idiopathic constipation (CIC), which was known to cause diarrhea and could limit its real-world use. Synergy's bid to improve upon Linzess helped shares peak at a $1.4 billion valuation in early 2017 (as shown in Figure 1, below).




Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up